OSI Pharmaceuticals Inc. is joining forces with AVEO Pharmaceuticals Inc. to advance a cancer drug platform targeting epithelial-to-mesenchymal transition (EMT), a marker believed to be associated with tumor development and progression. (BioWorld Today)